Product Description: FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729)[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Guo Q, et al., FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Oct 1;23(10):1367-1377. /[2]Guo Q, et al., FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Oct 1;23(10):1367-1377.
Molecular Weight: N/A
Compound Purity: 99.22
Research Area: Cancer
Target: ADC Antibody